Integrated plasma and urine metabolomics coupled with HPLC/QTOF-MS and chemometric analysis on potential biomarkers in liver injury and hepatoprotective effects of Er-Zhi-Wan

详细信息    查看全文

• 作者：Weifeng Yao (1) (2)
  Haiwei Gu (2) (5)
  Jiangjiang Zhu (2)
  Gregory Barding (2) (6)
  Haibo Cheng (3)
  Beihua Bao (1) (4)
  Li Zhang (1) (4)
  Anwei Ding (1) (4)
  Wei Li (1)
  
• 关键词：Integrated metabolomics ; Er ; Zhi ; Wan (EZW) ; Hepatoprotective ; HPLC/QTOF ; MS ; Chemometrics
• 刊名：Analytical and Bioanalytical Chemistry
• 出版年：2014
• 出版时间：November 2014
• 年：2014
• 卷：406
• 期：28
• 页码：7367-7378
• 全文大小：2,789 KB
• 参考文献：1. Griffin JL, Walker LA, Garrod S, Holmes E, Shore RF, Nicholson JK (2000) Comp Biochem Physiol, Part B: Biochem Mol Biol 127:357鈥?67 CrossRef
  2. Irie M, Fujimura Y, Yamato M, Miura D, Wariishi H (2014) Metabolomics 10:473鈥?83 CrossRef
  3. Li M, Li H, Jiang P, Liu XQ, Xu D, Wang F (2014) Mol BioSyst 10:1055鈥?062 CrossRef
  4. Zhao XJ, Zhang Y, Meng XL, Yin PY, Deng C, Chen J, Wang Z, Xu GW (2008) J Chromatogr B Anal Technol Biomed Life Sci 873:151鈥?58 CrossRef
  5. Antti H, Ebbels TMD, Keun HC, Bollard ME, Beckonert O, Lindon JC, Nicholson JK, Holmes E (2004) Chemom Intell Lab Syst 73:139鈥?49 CrossRef
  6. Beyo臒lu D, Idle JR (2013) J Hepatol 59(4):842鈥?58 CrossRef
  7. Qiu J (2007) Nature 448:126鈥?28 CrossRef
  8. Qiu J (2007) Nat Rev Drug Discov 6:506鈥?07 CrossRef
  9. Wang M, Lamers RJ, Korthout HJ (2005) Phytother Res 19:173鈥?82 CrossRef
  10. Gou X, Tao Q, Feng Q, Peng J, Sun S, Cao H (2013) J Pharm Biomed Anal 74:62鈥?5 CrossRef
  11. The National Pharmacopoeia Commission of P.R. China (2010) Pharmacopoeia of the People鈥檚 Republic of China, vol. 1. Chinese Medical Science and Technology Press, Beijing, pp 412鈥?13
  12. Zhang AH, Sun H, Dou SS, Sun WJ, Wu XH, Wang P, Wang XJ (2013) Analyst 138:353鈥?61 CrossRef
  13. Cai XJ, Yan B, Yao WF, Zhang L, Huang MY, Ding AW (2011) Chinese Pharmacological Bull 27(12):1774鈥?775
  14. Gao HL, Wang DQ, Wang XY (2010) Chin J Integr Med 16(6):504鈥?09 CrossRef
  15. Xu H, Su ZR, Huang W, Choi RC, Zheng YZ, Lau DT, Dong TT, Wang ZT, Tsim KW (2012) J Ethnopharmacol 143(1):109鈥?15 CrossRef
  16. Yan B, Cai XJ, Yao WF, Zhang L, Huang MY, Ding AW (2012) China JChin Mater Med 37(9):1303鈥?305
  17. Zhen C, Lifu S, Jinhong H, Qian S (1998) Acad J Sec Mil Med Univ 19(1):76鈥?8
  18. Kobori M, Yang Z, Gong D, Heissmeyer V, Zhu H, Jung YK, Gakidis MAM, Rao A, Sekine T, Ikegami F, Yuan C, Yuan J (2004) Cell Death Differ 11(1):123鈥?30 CrossRef
  19. Han DW, Ma XH, Zhao YC, Yin L, Ji CX (1982) J Tradit Chin Med 2(2):83鈥?0
  20. Liu J (2005) J Ethnopharmacol 100(1鈥?):92鈥?4 CrossRef
  21. Liu J, Liu Y, Klaassen CD (1994) J Ethnopharmacol 42(3):183鈥?91 CrossRef
  22. Liu J, Liu Y, Parkinson A, Klaassen CD (1995) J Pharmacol Exp Ther 275(2):768鈥?74
  23. Cheng M, Wang QW, Fan YK, Liu XY, Wang L, Xie RM, Ho CC, Sun WJ (2011) J Ethnopharmacol 138(2):279鈥?85 CrossRef
  24. Shimada T, Nakanishi T, Toyama A, Yamauchi S, Kanzaki A, Fujiwake H, Sato TA, Ikegawa M (2010) J Proteome Res 9(9):4490鈥?500 CrossRef
  25. Henkel C, Roderfeld M, Weiskirchen R, Berres ML, Hillebrandt S, Lammert F, Meyer HE, St眉hler K, Graf J, Roeb E (2006) Proteomics 6(24):6538鈥?548 CrossRef
  26. Atmaca M, Bilgin HM, Obay BD, Diken H, Kelle M, Kale E (2011) J Physiol Biochem 67(4):569鈥?76 CrossRef
  27. van Ginneken V, Verhey E, Poelmann R, Ramakers R, van Dijk KW, Ham L (2007) Biochim Biophys Acta 1771:1263鈥?270 CrossRef
  28. Garcia-Canaveras JC, Donato MT, Castell JV, Lahoz A (2011) J Proteome Res 10:4825鈥?834 CrossRef
  29. He M, Yao WF, Zhang L, Ding AW (2012) Zhongguo Zhong Yao Za Zhi 37(5):594鈥?96
  30. Nanji AA, Mendenhall CL, French SW (1989) Clin Exp Res 13(1):15鈥?9 CrossRef
  31. Ramsay JO, Ten Berge JMF, Styan GPH (1984) Psychometrika 49:403鈥?23 CrossRef
  32. Robert P, Escoufier Y (1976) Appl Stat 25:257鈥?65 CrossRef
  33. Smilde AK, Westerhuis JA, De Jong S (2003) J Chemom 17:323鈥?37 CrossRef
  34. Eriksson L, Johansson E, Kettaneh N, Trygg J, Wikstrom C, Wold S (2006) Multivariate and megavariate data analysis part I: basic principles and applications, second revised and enlarged edition. Sweden, Umetrics Academy, p 189
  35. Pierce KM, Hope JL, Johnson KJ, Wright BW, Synovec RE (2005) J Chromatogr A 1096:101鈥?10 CrossRef
  36. Smith CA, O鈥橫aille G, Want EJ, Qin C, Trauger SA, Brandon TR, Custodio DE, Abagyan R, Siuzdak G (2005) Ther Drug Monit 27(6):747鈥?51 CrossRef
  37. Wishart DS, Tzur D, Knox C. (2007) Nucleic Acids Res. (Database issue): D521-526.
  38. Kanehisa M (2002) Novartis Found Symp 247:91鈥?01 CrossRef
  39. Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS (2012) Nucleic Acids Res. 40(Web Server issue): W127-33.
  40. Eriksson L, Johansson E, Kettaneh N, Trygg J, Wikstrom C, Wold S (2006) Multivariate and megavariate data analysis part I: basic principles and applications, second revised and enlarged edition. Umetrics Academy, Sweden, p 97
  41. Van den Berg R, Hoefsloot HCJ, Westerhuis J, Smilde A, van der Werf MJ (2006) BMC Genomics 7:142 CrossRef
  42. Huang Y, Tian Y, Li G, Li Y, Yin X, Peng C, Xu F, Zhang Z (2013) Anal Bioanal Chem 405:4811鈥?822 CrossRef
  43. Zhang H, Fu P, Ke B, Wang S, Li M, Han L, Peng C, Zhang W, Liu R (2014) J Ethnopharmacol 154(1):55鈥?4 CrossRef
  44. Fujita T, Hada T, Higashino K (1999) Clin Chim Acta 287:145鈥?56 CrossRef
  45. Musiek ES, Yin H, Milne GL, Morrow JD (2005) Lipids 40(10):987鈥?94 CrossRef
  46. Cho HJ, Kim JD, Lee WY, Chung BC, Choi MH (2009) Anal Chim Acta 632(1):101鈥?08 CrossRef
  47. Zhang AH, Sun H, Sun WJ, Jiao GZ, Wang XJ (2013) Anal Methods 5:5294鈥?301 CrossRef
  48. Park SW, Kim M, Chen SW, Brown KM, D鈥橝gati VD, Lee HT (2010) Lab Investig 90(8):1209鈥?224 CrossRef
  49. Natasha CL, Marion BS (2010) Steroids 75(6):390鈥?99 CrossRef
  50. Fujita T, Amuro Y, Hada T, Higashino K (1999) Clin Chim Acta 287(1鈥?):99鈥?09 CrossRef
  51. Matsuda Y, Fujita T, Hada T, Higashino K (2000) Hepatol Res 18(2):132鈥?40 CrossRef
  52. Bernard LH (2002) J Biol Chem 277(50):47965鈥?7971 CrossRef
  53. Kunjara MS, Ali SA, Greenbaum AL, McLean P (1987) Biochem J 244:101鈥?08
  
• 作者单位：Weifeng Yao (1) (2)
  Haiwei Gu (2) (5)
  Jiangjiang Zhu (2)
  Gregory Barding (2) (6)
  Haibo Cheng (3)
  Beihua Bao (1) (4)
  Li Zhang (1) (4)
  Anwei Ding (1) (4)
  Wei Li (1)
  
  1. College of Pharmacy, Nanjing University of Chinese Medicine, 210023, Nanjing, Jiangsu, China
  2. Northwest Metabolomics Research Center, Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, 98109, USA
  5. Jiangxi Key Laboratory for Mass Spectrometry and Instrumentation, East China Institute of Technology, 330013, Nanchang, Jiangxi, China
  6. Department of Chemistry and Biochemistry, California State Polytechnic University, Pomona, CA, 91768, USA
  3. Jiangsu Engineering Laboratory for Research and Industrialization of Empirical Formulae, Nanjing University of Chinese Medicine, 210023, Nanjing, Jiangsu, China
  4. Jiangsu Key Laboratory for Traditional Chinese Medicine Formulae Research, Nanjing University of Chinese Medicine, 210023, Nanjing, Jiangsu, China
  
• ISSN：1618-2650

文摘

Metabolomics techniques are the comprehensive assessment of endogenous metabolites in a biological system and may provide additional insight into the molecular mechanisms. Er-Zhi-Wan (EZW) is a traditional Chinese medicine formula, which contains Fructus Ligustri Lucidi (FLL) and Herba Ecliptae (HE). EZW is widely used to prevent and treat various liver injuries through the nourishment of the liver. However, the precise molecular mechanism of hepatoprotective effects has not been comprehensively explored. Here, an integrated metabolomics strategy was designed to assess the effects and possible mechanisms of EZW against carbon tetrachloride-induced liver injury, a commonly used model of both acute and chronic liver intoxication. High-performance chromatography/quadrupole time-of-flight mass spectrometry (HPLC/QTOF-MS) combined with chemometric approaches including principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA) were used to discover differentiating metabolites in metabolomics data of rat plasma and urine. Results indicate six differentiating metabolites, tryptophan, sphinganine, tetrahydrocorticosterone, pipecolic acid, l-2-amino-3-oxobutanoic acid and phosphoribosyl pyrophosphate, in the positive mode. Functional pathway analysis revealed that the alterations in these metabolites were associated with tryptophan metabolism, sphingolipid metabolism, steroid hormone biosynthesis, lysine degradation, glycine, serine and threonine metabolism, and pentose phosphate pathway. Of note, EZW has a potential pharmacological effect, which might be through regulating multiple perturbed pathways to the normal state. Our findings also showed that the robust integrated metabolomics techniques are promising for identifying more biomarkers and pathways and helping to clarify the function mechanisms of traditional Chinese medicine. Graphical Abstract Overview of the integrated metabolomics strategy